HOME >> MEDICINE >> NEWS
New compound unusually potent at blocking brain cancer growth

By determining how a class of compounds blocks signaling in cells, UCSF scientists have identified what is perhaps the most potent drug candidate yet against a highly lethal kind of brain tumor.

The compound, known as PI-103, shows unique potency against cancer cell proliferation in studies of mice with grafts of human glioma cells. Gliomas are the most common form of brain cancer, and have proven very difficult to treat.

The unique effectiveness of PI-103 stems from its ability to attack two separate steps in the series of signals that trigger the spread of cancer. The dual blockade proved to be a safe and effective inhibitor of cancer cell proliferation in mice with the human tumors, the scientists found.

The glioma research is being published online May 15 by the journal Cancer Cell. A description of the strategy used to identify the molecular level action of the inhibitors was published online by the journal Cell on April 27.

Food and Drug Administration approval five years ago of the cancer drug Gleevec marked a promising new strategy against cancer. Gleevec was the first drug on the market designed to block ubiquitous signaling molecules called protein kinases enzymes known to trigger normal cell proliferation, and in the case of cancer, the growth of tumors. Another group of kinases, called lipid kinases are now emerging as important new targets, especially PI3 alpha kinase, an enzyme often found to be overactive in brain, breast, colon and stomach cancers.

But the sheer number of related kinases 15 in the PI3 kinase family alone and uncertainty about how each acts in the body has stalled progress. Broad spectrum drugs that inhibit many related kinases inevitably cause toxicity and are poor drug candidates.

To overcome this hurdle, Kevan Shokat, PhD, a Howard Hughes Medical Institute investigator at UCSF, and Zachary Knight, a postdoctoral fellow in his lab, developed a strategy to systematically inhibit many different but r
'"/>

Contact: Wallace Ravven
wravven@pubaff.ucsf.edu
415-476-2557
University of California - San Francisco
15-May-2006


Page: 1 2 3

Related medicine news :

1. New oxidation methods streamline synthesis of important compounds
2. AMPAKINE compounds a new potential treatment for respiratory depression
3. Green tea compound suppresses factors causing cartilage, bone destruction in arthritis
4. Green tea compound may be a therapy for people with rheumatoid arthritis
5. Anti-dandruff compound may help fight epilepsy
6. Depression among retired NFL players: Rates mirror the general public, but pain compounds symptoms
7. Chromium 6: A killer compound with an improbable trigger
8. New compound shows promise in halting HIV spread
9. New imaging compound might see Alzheimers earlier
10. U of M researchers discover compounds to shrink tumors
11. Diagnosis and treatment of osteoporosis falls shortnon adherence compounds issue

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2017)... ... , ... People are starting to accept that hearing aids can be helpful ... stigma it had when great-grandpa wore his hearing aids years ago,” said Dr. Maura ... North American Speaker Series (NASS) segment. “He probably wore an iPod-size hearing aid ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... pilot study of ActiGraph’s CentrePoint Data Hub in a sample of ... of clinical-grade wearable activity and sleep monitoring solutions for the global scientific community. ...
(Date:4/28/2017)... New York (PRWEB) , ... April 28, 2017 ... ... anti-aging skincare and advanced nutraceutical supplements, through its Nova Skin Sciences ... provides the hydrating benefits of a moisturizer with the power of an anti-aging ...
(Date:4/28/2017)... ... April 28, 2017 , ... Semrock’s ... is the premier online modeling resource for fluorescence microscopists and optical system designers, ... during last 5 years spanning the globe, SearchLight has become a tremendously popular ...
(Date:4/27/2017)... ... April 27, 2017 , ... The Incentive Research ... Recognition: A Nudge Guide," a groundbreaking analysis of how behavioral economics can be ... apply immediately to IRR programs, the report highlights proven behavioral economics approaches and ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017  New research provides evidence that ... Parkinson,s, according to a study released today that will be ... Meeting in Boston , April 22 ... the treatment of Parkinson,s disease, the oral drug levodopa has ... and longevity. But as the disease progresses, the effects of ...
(Date:4/18/2017)... -- Cardinal Health (NYSE: CAH ) today is ... share (EPS) guidance and providing a preliminary view on ... this morning,s announcement of the planned acquisition of Medtronic,s ... Cardinal Health now believes that fiscal 2017 ... bottom of its previous guidance range of $5.35 to ...
(Date:4/18/2017)... 2017 Research and Markets has announced the ... to their offering. ... arthroscopy devices market to grow at a CAGR of 6.35% during ... Market 2017-2021, has been prepared based on an in-depth market analysis ... and its growth prospects over the coming years. The report also ...
Breaking Medicine Technology:
Cached News: